Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2017

View Archived Issues

Sarepta's phase I/II study of golodirsen in DMD meets primary biological endpoint

GSK exercises option to develop and commercialize SPEAR T-cell therapy program targeting NY-ESO

Phase IIb trial of upadacitinib in atopic dermatitis meets primary endpoint

Intra-Cellular Therapies reports data from first part of lumateperone study

Clinical results presented for JNJ-42847922/MIN-202 in insomnia and major depression

Tyme reports positive results from long-term analysis of SM-88 trial in metastatic cancer

Boehringer Ingelheim and Gubra to develop treatments for obesity

Rutgers University discovers novel chemical entities for treating tuberculosis

Iovance Biotherapeutics and Ohio State University enter preclinical research collaboration

Novartis presents new analyses on AMG-334

FDA awards breakthrough therapy designation to cemiplimab for advanced CSCC

Amylyx Pharmaceuticals enters collaboration with Project ALS

SBIR grant supports Oligomerix's development of Alzheimer's disease specific antibody biomarker

VSV-GP shows promising in vitro results for the treatment of lung cancer

FDA places clinical hold on durvalumab studies

Lyndra and Allergan partner to develop ultra-long-acting Alzheimer's treatment

Alnylam updates status of fitusiran and givosiran development programs

Bristol-Myers Squibb completes acquisition of IFM Therapeutics

miRNAs found to impact MDD treatment response

Shanghai Institute Materia Medica discovers new FGFR inhibitors

Sumitomo Dainippon Pharma generates novel imidazolylamide derivatives

New 5' AMP-activated protein kinase activators discovered at Shionogi & Co.

R-Pharm CJSC presents novel serine/threonine-protein kinase B-raf inhibitors

Asceneuron patents N-acetyl-beta-D-glucosaminidase inhibitors

Eisai and Ono collaborate to develop Lenvima and Opdivo combination for HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...